Biotech News
Related news
EDITEditas Medicine2026-10-14 13:00 EST
Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference
MGTXMeiraGTx2026-09-23 12:00 EST
MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors
CRSPCRISPR Therapeutics2026-11-04 14:01 EST
CRISPR Therapeutics to Present Clinical Data from Zugo-cel in Large B-Cell Lymphoma at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition
OCGNOcugen2026-10-14 10:30 EST
Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
TSHATaysha Gene Therapies2026-10-01 12:00 EST
Taysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual Meeting
CRBUCaribou2026-11-04 14:00 EST
Caribou Biosciences Announces Presentations at the 2026 American Society of Hematology (ASH) Annual Meeting
BCRXBioCryst Pharmaceuticals2026-10-29 11:00 EST
BioCryst to Present New Data for ORLADEYO® (berotralstat) and Navenibart at the 2026 American College of Allergy, Asthma & Immunology Annual Scientific Meeting
VYGRVoyager Therapeutics2026-10-27 12:01 EST
Voyager’s Tau-Targeted Gene Therapy VY1706 and Anti-Tau Antibody VY7523 for Alzheimer’s Disease to Be Featured in Poster Presentations at CTAD 2026
SRPTSarepta Therapeutics2026-10-14 12:30 EST
Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting
SRPTSarepta Therapeutics2026-09-30 12:30 EST
Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with Duchenne
MeiraGTx
Genetic Medicines Company MeiraGTx develops and manufactures gene therapies for inherited retinal disease, salivary-gland disorders, and other conditions. Its vertically integrated model spans vector design, clinical development, and commercial manufacturing. Bota-Vec Botaretigene sparoparvovec is an AAV gene therapy for X-linked...
Recent company news
MGTXMeiraGTx2026-10-27 12:00 EST
MeiraGTx Announces Four Posters at the European Society of Gene and Cell Therapy (ESGCT) 2026 Annual Congress and the Network of Excellence for ALS (NEALS) Annual Meeting
MGTXMeiraGTx2026-09-23 12:00 EST
MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors
MGTXMeiraGTx2026-08-13 12:00 EST
MeiraGTx Reports Second Quarter 2026 Financial and Operational Results
MGTXMeiraGTx2026-08-06 20:30 EST
MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MGTXMeiraGTx2026-07-07 11:30 EST
MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)
Stock data
- Close
- 8.51 USD
- Market cap
- 855.71M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States